Kristie L. Kahl

The Food and Drug Administration approved Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

The Food and Drug Administration approved Xtandi for the treatment of patients with metastatic castration-sensitive prostate cancer.

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

As a 20-something med student facing a rare disease, Dr. David C. Fajgenbaum took matters into his own hands to find his own treatment.

The Food and Drug Administration approved the first generic for Afinitor, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

The Food and Drug Administration approved Tecentriq in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations.

The FDA accepted a supplemental biologics license application (sBLA) and granted a priority review to Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC), according to AstraZeneca, the drug’s manufacturer.

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma – a cancer that originates in the bile ducts – with FGFR2 fusions or rearrangements, according to Incyte, the agent’s manufacturer.

Here is a list of the recent trial initiations that occurred within the cancer space in November.

In this week’s “CURE Talks Cancer” podcast, we spoke with Michelle Velez, who developed a rare gynecological cancer following a molar pregnancy.

The Food and Drug Administration’s approval of Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option, according to Dr. John C. Byrd.

The keynote speaker at the CURE® Patient-Focused Sessions at the Annual New York Lung Cancers Symposium® heeded warning signs and urges others to do the same.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Mark Socinski to learn more about stage 3 lung cancer and what others should know about the disease.

A nurse practitioner explains why it is key for patients with lung cancer being treated with immunotherapy to be aware of the treatment’s potential side effects.

The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.

Forty-eight percent of those surveyed by The Pink Fund said the cost of transportation was a barrier to receiving treatment and 60% missed an appointment or were late to one because of transportation issues.

Here is a list of the recent trial initiations that occurred within the cancer space in October.

In this episode of the “CURE Talks Cancer” podcast, we spoke with Scott Petinga, who was diagnosed with and overtreated for his stage 1 testicular cancer, about his journey and how he now advocates for other patients.

The Metastatic Breast Cancer Alliance (MBCA) launched a campaign to bring awareness of clinical trials to more individuals and encourage them to speak with their health care teams about them.

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

Now a 10-year survivor of bone cancer, Dana Vaughns chose to triumph over his disease and joined Bristol-Myers Squibb on its Coast 2 Coast 4 Cancer ride.

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

Frontline treatment with Opdivo improved overall survival and response rates among patients with advanced hepatocellular carcinoma, however, the trial missed its primary endpoint.

In this episode of the “CURE Talks Cancer” podcast, Twist Out Cancer founder Jenna Benn Shersher shares on her journey with grey zone lymphoma and how her organization helps pair individuals to use art as an outlet to cope through cancer.

The IMvigor130 trial showed chemotherapy plus immunotherapy in patients with metastatic urothelial cancer could prolong the time to disease progression.

Two patients with metastatic breast cancer shared their journeys, inspiring fellow patients at Susan G. Komen Greater New York City’s New York Metastatic Breast Cancer Conference.